Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
76 hedge funds and large institutions have $410M invested in Aerie Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 7 reducing their positions, and 8 closing their positions.
414% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 7
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
27% more funds holding
Funds holding: 60 → 76 (+16)
4% more capital invested
Capital invested by funds: $392M → $410M (+$17.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$19.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.7M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.9M |
| 4 |
JP Morgan Chase
New York
|
+$4.85M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
-$19.7M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$725K |
| 3 |
WSA
Wall Street Associates
Lajolla,
California
|
-$678K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$401K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$277K |
AERI Hedge Fund Activity: Q3 2014 in Review
76 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2014, worth a combined $410M — up 4.5% from $392M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AERI positions and 8 closed out — a net gain of 16 holders — while 36 added to existing stakes and 7 trimmed.
The largest buyer was Deerfield Management, adding an estimated $19.2M. The largest seller was TPG Group Holdings (SBS) Advisors, cutting an estimated $19.7M.
- 76 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2014, up from 60 in Q2 2014.
- Funds reported $410M of Aerie Pharmaceuticals stock for Q3 2014, up 4.5% quarter-over-quarter.
- 24 funds opened new Aerie Pharmaceuticals positions in Q3 2014 and 8 closed out, a net change of +16 holders.
- The largest Aerie Pharmaceuticals buyer in Q3 2014 was Deerfield Management, an estimated $19.2M added.
- The largest Aerie Pharmaceuticals seller in Q3 2014 was TPG Group Holdings (SBS) Advisors, an estimated $19.7M sold.
Based on aggregated 13F filings for Q3 2014.